Indivior Real World Evidence Study Finds Long-Acting Medications For Opioid Use Disorder Linked To Lower Odds Of Emergency Department Visits 

Health care claims data indicate lower odds of emergency department (ED) visits among people with opioid use disorder (OUD) treated with an injected, extended-release buprenorphine (BUP-XR) formulation as a medication to treat opioid use disorder (MOUD), according to a study funded by Indivior, which manufactures and markets buprenorphine medications. The odds of an ED visit for those treated with BUP-XR were lower than those for people with OUD treated with daily oral buprenorphine (no numbers given) and 57% lower than those not offered MOUD. ED visits related to opioid overdose ranged from zero for those treated with . . .